Need to focus on some ...

It is necessary to highlight some general principles on the use of antidepressants. Monotherapy with the basic requirement for modern treatment of depression: the appointment of a selected product and its use for at least 4 weeks, reaching the maximum tolerated therapeutic dose is desirable to 7-14 day of treatment. In this case, tolerance may allow moderately expressed transient side effects, about which the patient is warned in advance and is willing to suffer for the sake of the main therapeutic outcome, which (and this also needs to know the patient) is usually not expected before the end of the 1 st, and often at the 3 - her week of therapy. In addition to biological intolerance (cholinolytic particular expression or other side effects), it is necessary to consider the possible psychological intolerance of particular sensitivity, nevynoslivost patient to some, even quite mild side effects. Sometimes it is excused in a special (and regular) the patient's attention to the preservation and maintenance of some relevance to the daily activities of functions: the unacceptability of even a light tremor of fingers in musicians, dry mouth for teachers, etc. But often psychological intolerance associated with particular sensitivity to pain, physical discomfort, sensory, as personality traits. Recognizing the important principle of modern single-agent treatment of depression can be considered justified in some types of complementary, concurrent therapy: 1) the so-called Therapy cover, which usually precedes the main purpose of antidepressant, and 2) adjuvant therapy, join the main to enhance or stabilize the main action of antidepressant. Therapy is mainly limited to cover the somatotropic and neurometabolic drugs and is focused on mitigating or preventing the reactions of organic and somatic changes of the soil. It can be antihypertensives (preferred b-blockers), vegetostabiliziruyuschie drugs (benzodiazepines are used mainly symptomatic); cerebroprotective funds (primarily nootropics) are appointed at the expressed cognitive impairment, especially if these phenomena were detected during the previous courses of therapy and impede full remission and re-socialization patient. However, the appointment of adjuvant therapy is preferable to defer to the stage, allowing to evaluate therapeutic options (efficacy and safety) of the main therapeutic agent. In particular as it relates to cognitive impairment and psycho-vegetative manifestations (reflecting somatization of mood disorders), because in most cases, these disorders are closely linked with depression and are reduced with the reduction of its main manifestations of affective (depression, anxiety), motivational and volitional (the inducement to activity) and vital (depression and change drives). To some extent, to the adjuvant drugs can be classified timostabilizatory, in particular, carbamazepine, whose accession to the stage to achieve the effect and end the active antidepressant therapy is justified not only to smooth out the emotional and autonomic instability common to complete the main therapy, but also to the subsequent long antirelapse treatment actually prevent worsening and recurrence of depression and general mood fluctuations in the probability of their occurrence.